thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on November 12, 2026

Blackstone offers Pfizer up to $1.5 billion for berobenatide development

Neurosterix raised $105 million for its schizophrenia program. Orakl Oncology raised $34 million, while Novo committed $200 million to the World Diabetes Federation.

  • Updated
  • Read from 9 articles, 6 publications
  • P B P

Today in brief

Blackstone Life Sciences agreed to cover up to $1.5 billion of Pfizer’s berobenatide development costs through 2028, with potential payments tied to US approval and sales milestones.123 Neurosterix raised $105 million to move its schizophrenia candidate NTX-253 toward Phase 2.4

Orakl Oncology secured $34 million to expand its AI platform for predicting cancer drug responses.5 Novo committed $200 million to support the World Diabetes Federation.6

Blackstone will cover up to $1.5 billion of Pfizer’s berobenatide costs

Blackstone Life Sciences agreed to fund up to $1.5 billion of development costs for Pfizer’s investigational monthly GLP-1 drug berobenatide through 2028.123 Blackstone may receive milestone payments if the drug wins US approval for chronic weight management and meets specified sales targets.123

Pfizer retains control of the program and its decisions, while Blackstone gets no ownership or rights to the drug.123 In a Phase 2b study, monthly berobenatide produced up to 12.3% greater weight loss than placebo at 28 weeks.278

Pfizer plans 10 ongoing or planned Phase 3 berobenatide studies as part of a broader program of more than 20 trials for obesity and related conditions in 2026.1237

Neurosterix raises $105 million for schizophrenia drug

Neurosterix raised $105 million in a Series B led by RTW Investments to advance NTX-253, its oral schizophrenia candidate, toward Phase 2.4 NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor, designed to amplify the receptor’s response to acetylcholine.4

Neurosterix said it completed Phase 1 studies in healthy volunteers and people with stable schizophrenia in October.4 The company said the studies support once-daily oral dosing, but NTX-253’s clinical efficacy has not been demonstrated.4

Neurosterix plans to start Phase 2 but has not set a date.4 It is also developing NTX-819 for mood and anxiety disorders and NTX-529 for other psychosis- and mood-related uses.4

Also worth knowing

  • Orakl Oncology raised $34 million in a Series A to expand its platform, which combines patient-derived tumor models and AI to predict cancer drug responses.5

  • P

    Novo committed $200 million to support the World Diabetes Federation.6

  • Johnson & Johnson led an investment in Francis Medical to support development of its prostate-cancer water-vapor therapy device.9

Also published